Beneficial Paracrine Effects of Cannabinoid Receptor 2 on Liver Injury and Regeneration

Overview

Journal Hepatology

Specialty Gastroenterology

Date 2010 Jul 3

PMID 20597071

Citations 50

Authors

Fatima Teixeira-Clerc

Marie-Pierre Belot

Sylvie Manin

Vanessa Deveaux

Thomas Cadoudal

Marie-Noele Chobert

Alexandre Louvet

Andreas Zimmer

Thierry Tordjmann

Ariane Mallat

Sophie Lotersztajn

Affiliations

Soon will be listed here.

Abstract

Unlabelled: The cannabinoid receptor 2 (CB2) plays a pleiotropic role in innate immunity and is a crucial mediator of liver disease. In this study, we investigated the impact of CB2 receptors on the regenerative process associated with liver injury. Following acute hepatitis induced by carbon tetrachloride (CCl(4)), CB2 was induced in the nonparenchymal cell fraction and remained undetectable in hepatocytes. Administration of CCl(4) to CB2(-/-) mice accelerated liver injury, as shown by increased alanine/aspartate aminotransferase levels and hepatocyte apoptosis, and delayed liver regeneration, as reflected by a retarded induction of hepatocyte proliferating cell nuclear antigen expression; proliferating cell nuclear antigen induction was also delayed in CB2(-/-) mice undergoing partial hepatectomy. Conversely, following treatment with the CB2 agonist JWH-133, CCl(4)-treated WT mice displayed reduced liver injury and accelerated liver regeneration. The CCl(4)-treated CB2(-/-) mice showed a decrease in inducible nitric oxide synthase and tumor necrosis factor-alpha expression, and administration of the nitric oxide donor moldomine (SIN-1) to these animals reduced hepatocyte apoptosis, without affecting liver regeneration. Impaired liver regeneration was consecutive to an interleukin-6 (IL-6)-mediated decrease in matrix metalloproteinase 2 (MMP-2) activity. Indeed, CCl(4)-treated CB2(-/-) mice displayed lower levels of hepatic IL-6 messenger RNA and increased MMP-2 activity. Administration of IL-6 to these mice decreased MMP-2 activity and improved liver regeneration, without affecting hepatocyte apoptosis. Accordingly, administration of the MMP inhibitor CTTHWGFTLC to CCl(4)-treated CB2(-/-) mice improved liver regeneration. Finally, in vitro studies demonstrated that incubation of hepatic myofibroblasts with JWH-133 increased tumor necrosis factor-alpha and IL-6 and decreased MMP-2 expressions.

Conclusion: CB2 receptors reduce liver injury and promote liver regeneration following acute insult, via distinct paracrine mechanisms involving hepatic myofibroblasts. These results suggest that CB2 agonists display potent hepatoprotective properties, in addition to their antifibrogenic effects.

Citing Articles

New insights in the pathogenesis of alcohol-related liver disease: The metabolic, immunologic, and neurologic pathways.

Ryu T, Kim K, Choi S, Chung K, Jeong W Liver Res. 2025; 7(1):1-8.

PMID: 39959703 PMC: 11791844. DOI: 10.1016/j.livres.2022.09.004.

The possible pathogenesis of liver fibrosis: therapeutic potential of natural polyphenols.

Niu C, Zhang J, Okolo P Pharmacol Rep. 2024; 76(5):944-961.

PMID: 39162986 DOI: 10.1007/s43440-024-00638-w.

CBD and THC in Special Populations: Pharmacokinetics and Drug-Drug Interactions.

Qian L, Beers J, Jackson K, Zhou Z Pharmaceutics. 2024; 16(4).

PMID: 38675145 PMC: 11054161. DOI: 10.3390/pharmaceutics16040484.

A UPLC-MS/MS method for simultaneous determination of arachidonic acid, stearic acid, and related endocannabinoids in human plasma.

Qian X, Liu W, Chen Y, Zhang J, Jiang Y, Pan L Heliyon. 2024; 10(7):e28467.

PMID: 38560270 PMC: 10979285. DOI: 10.1016/j.heliyon.2024.e28467.

Monoacylglycerol lipase reprograms hepatocytes and macrophages to promote liver regeneration.

Allaire M, Sayegh R, Mabire M, Hammoutene A, Siebert M, Caer C JHEP Rep. 2023; 5(8):100794.

PMID: 37520673 PMC: 10382928. DOI: 10.1016/j.jhepr.2023.100794.

References

Osei-Hyiaman D, Depetrillo M, Pacher P, Liu J, Radaeva S, Batkai S . Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005; 115(5):1298-305. PMC: 1087161. DOI: 10.1172/JCI23057. View

Luedde T, Trautwein C . Intracellular survival pathways in the liver. Liver Int. 2006; 26(10):1163-74. DOI: 10.1111/j.1478-3231.2006.01366.x. View

Trim N, Morgan S, Evans M, Issa R, Fine D, Afford S . Hepatic stellate cells express the low affinity nerve growth factor receptor p75 and undergo apoptosis in response to nerve growth factor stimulation. Am J Pathol. 2000; 156(4):1235-43. PMC: 1876895. DOI: 10.1016/S0002-9440(10)64994-2. View

Aram G, Potter J, Liu X, Torbenson M, Mezey E . Lack of inducible nitric oxide synthase leads to increased hepatic apoptosis and decreased fibrosis in mice after chronic carbon tetrachloride administration. Hepatology. 2008; 47(6):2051-8. DOI: 10.1002/hep.22278. View

Teixeira-Clerc F, Julien B, Grenard P, Tran Van Nhieu J, Deveaux V, Li L . CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med. 2006; 12(6):671-6. DOI: 10.1038/nm1421. View

Munoz-Luque J, Ros J, Fernandez-Varo G, Tugues S, Morales-Ruiz M, Alvarez C . Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther. 2007; 324(2):475-83. PMC: 2887659. DOI: 10.1124/jpet.107.131896. View

Hezode C, Zafrani E, Roudot-Thoraval F, Costentin C, Hessami A, Bouvier-Alias M . Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology. 2008; 134(2):432-9. DOI: 10.1053/j.gastro.2007.11.039. View

Jin X, Zimmers T, Perez E, Pierce R, Zhang Z, Koniaris L . Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair. Hepatology. 2006; 43(3):474-84. DOI: 10.1002/hep.21087. View

Siegmund S, Qian T, De Minicis S, Harvey-White J, Kunos G, Vinod K . The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species. FASEB J. 2007; 21(11):2798-806. DOI: 10.1096/fj.06-7717com. View

10.

Steffens S, Veillard N, Arnaud C, Pelli G, Burger F, Staub C . Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature. 2005; 434(7034):782-6. DOI: 10.1038/nature03389. View

11.

Buckley N, McCOY K, Mezey E, Bonner T, Felder C, Glass M . Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol. 2000; 396(2-3):141-9. DOI: 10.1016/s0014-2999(00)00211-9. View

12.

Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K . Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A. 2006; 103(3):696-701. PMC: 1334629. DOI: 10.1073/pnas.0504187103. View

13.

Julien B, Grenard P, Teixeira-Clerc F, Tran Van Nhieu J, Li L, Karsak M . Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology. 2005; 128(3):742-55. DOI: 10.1053/j.gastro.2004.12.050. View

14.

RAI R, Lee F, Rosen A, Yang S, Lin H, Koteish A . Impaired liver regeneration in inducible nitric oxide synthasedeficient mice. Proc Natl Acad Sci U S A. 1998; 95(23):13829-34. PMC: 24912. DOI: 10.1073/pnas.95.23.13829. View

15.

Pacher P, Batkai S, Kunos G . The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006; 58(3):389-462. PMC: 2241751. DOI: 10.1124/pr.58.3.2. View

16.

Fausto N, Campbell J, Riehle K . Liver regeneration. Hepatology. 2006; 43(2 Suppl 1):S45-53. DOI: 10.1002/hep.20969. View

17.

Taub R . Liver regeneration: from myth to mechanism. Nat Rev Mol Cell Biol. 2004; 5(10):836-47. DOI: 10.1038/nrm1489. View

18.

Serriere-Lanneau V, Teixeira-Clerc F, Li L, Schippers M, de Wries W, Julien B . The sphingosine 1-phosphate receptor S1P2 triggers hepatic wound healing. FASEB J. 2007; 21(9):2005-13. DOI: 10.1096/fj.06-6889com. View

19.

Lotersztajn S, Julien B, Teixeira-Clerc F, Grenard P, Mallat A . Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol. 2004; 45:605-28. DOI: 10.1146/annurev.pharmtox.45.120403.095906. View

20.

Sanz S, Pucilowska J, Liu S, Rodriguez-Ortigosa C, Lund P, Brenner D . Expression of insulin-like growth factor I by activated hepatic stellate cells reduces fibrogenesis and enhances regeneration after liver injury. Gut. 2004; 54(1):134-41. PMC: 1774353. DOI: 10.1136/gut.2003.024505. View